Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation
Patent 5902786 Issued on May 11, 1999. Estimated Expiration Date: April 15, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/21, Produced by or extracted from animal tissue514/44, Polynucleotide (e.g., RNA, DNA, etc.)514/885IMMUNE RESPONSE AFFECTING DRUG
The present invention discloses a method for treating patients having basal cell carcinoma comprising subcutaneous, intralesional or topical administration of Product R, a peptide-nucleic acid preparation.
Other References
Ragni et al., Blood, 81:1889-1897, 1993
Reynolds, Margaret R., Generalized Vaccinia, Symposium, pp. 5-6, 1960
Kuckku, Morris E., Herpetic Diseases, Symposium, pp. 7-13, 1960
Schaeffer, Oden A., Influenza, Symposium, pp. 15-21, 1960
Seydel, Frank, Epidemic, Asian Influenza, Symposium, pp. 23-24, 1960
Cooke, Stanford B., Upper Respiratory Viral Manifestations, Clinical Symposium on Viral Diseases Demonstrating the Anti-viral Biotic Properties of the Drug Reticulose (Symposium), Sep., 1960, Miami Beach, Florida, pp. 25-32
Medoff, Lawrence R., Infectious Mononucleosis, Symposium, pp. 33-37, 1960
Anderson, Robert H., Encephalitis, Symposium, pp. 39-52, 1960
Plucinski, Stanisloff J., Suspected Viral Varieties, Symposium, pp. 53-59, 1960
Kosaka, K. and Shimada, Y., Infectious Hepatitis, Symposium, pp. 61-74, 1960
Anderson, Robert H. and Thompson, Ralph M., Treatment of Viral Syndrome with a Lipoprotein-Nucleic Acid Compound (Reticulose), A Report of Five Cases, Virginia Medical Monthly, 84: 347-353, 1957
Reynolds, Margaret R., Generalized Vaccinia Successfully Treated With Lipoprotein-Nucleic Acid Complex (Reticulose), Archives of Pedratrics, 77:421-422, 1960
Wegryn, Stanley P., Marks, Robert A. and Baugh, John R., Herpes Gestationis, A Report of 2 Cases, American Journal of Obstetrics and Gynecology, 79:812-814, 1960
Catterall, R.A., Lumpur, Kuala, A New Treatment of Herpes Zoster, Vaccinia And Chicken Pox, J. Roy, Coll. Gen. Practit., 1970, 19, 182
Chinnici, Angelo A., Reticulose in Treatment Aids patients, Personal Communication to William Bregman, Jul. 6, 1992
Cott, Rafael A., Summary of 11 Cases of Viral Infections with Reticulose, Private Communication with Advance Viral Research Corp., 1989
Cohen, Matthew, The Efficacy of a Peptide-Nucleic Acid Solution (Reticulose) for the Treatment of Hepatitis A and Hepatitis B--a Preliminary Controlled Human Clinical Trial, J. Roy Soc. Health, Dec., 1992, 266-270
Mundschenk, David D., In Vitro Antiviral Activity of Reticulose vs Influenaz A, Personal Communication with William Bregman, May 1, 1990
Resnick, Lionel, Anti-HIV in Vitro Activity of Two Samples of Peptide-nucleic Acid Solution, Personal Communication with Dr. Bernard Friedland, Dec. 22, 1989
Friedland, Bernard, In Vitro Antiviral Activity of a Peptide-Nucleic Acid Solution Against the Human Immunodeficiency Virus and Influenza A Virus, J. Roy. Soc. Health, Oct. 1991, 170-171
Brazier, Anne D., Method for in Vitro Antiviral Evaluation Human Immunodeficiency Virus (HIV), Personal Communication with Dr. Bernard Friedland, Oct. 4, 1989
Behbehani, Abbas M., Haberman Sol and Race, George J, The Effect of Reticulose on Viral Infections of Experimental Animals, Southern Medical Journal, Feb., 1962, 185-188
Treatment of Viral Diseases with A Lipo-protein Nucleic Acid Complex (Reticulose)--A Clinical Study, Scientific Exhibit: Virginia State Medical Society Meeting, Washington D.C., Nov., 1957
Kempe, Henry C., Fulginiti, Vincent A., and Vincent, Leone St., Failure to Demonstrate Antiviral Activity of Reticulose, Diseases of Children, vol. 103, No. 5, 655-657, 1962
Sanders, Murray, Controlled Animal Studies with Reticulose Illustrating of Lipoprotein-Nucleic Acid Complex in the Experimental Animal Infected with Human Pathogenic Viral Entities, Southern Medical Association Scientific Exhibit, Dallas, Texas, Nov., 196
April 15, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
